Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Sanfilippo RSU Tax Withholding Sale: 1,522 Shares at $8.86

WhiteFiber, Inc. Chief Technology Officer Thomas Sanfilippo filed a Form 4 on November 13, 2026, disclosing a disposition of 1,522 ordinary shares on November 10, 2026, in connection with RSU vesting.

Manish Choudhary | 13 November 2026

Sensata EVP Caljouw Sells 7,726 Shares Under 10b5-1 Plan

Lynne J. Caljouw, Executive Vice President and Chief HR Officer of Sensata Technologies Holding plc, filed a Form 4 on November 13, 2026, disclosing the sale of 7,726 ordinary shares on November 10, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Aditi Sarkar | 13 November 2026

Dyer Acquires 18,857,075 Stock Options in Addex Therapeutics

Timothy Mark Dyer, Chief Executive Officer and Director of Addex Therapeutics Ltd. (NASDAQ:ADXN), filed a Form 4 on November 13, 2026, disclosing the acquisition of stock options on November 11, 2026.

Aditi Sarkar | 13 November 2026

Addex Director Nunn Receives 942,854 Stock Options

Director Jason Raleigh Nunn of Addex Therapeutics Ltd. filed a Form 4 on November 13, 2026, disclosing the acquisition of 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share.

Vinay Lochav | 13 November 2026

Addex Director Isaac Manke Receives 942,854 Stock Options

Director Isaac Manke filed a Form 4 with the SEC on November 13, 2026, reporting the acquisition of 942,854 stock options in Addex Therapeutics Ltd. (NASDAQ:ADXN) on November 11, 2026.

Anjali Anand | 13 November 2026

Appian Director Lynch Sells 9,533 Shares at $53.14

Director Mark Steven Lynch filed a Form 4 with the SEC on November 13, 2026, disclosing the sale of 9,533 shares of Appian Corporation Class A Common Stock on November 11, 2026.

Manish Choudhary | 13 November 2026

Teyssedou Receives 3,771,415 Options in Addex Therapeutics

Lenaic Nathanael Teyssedou, Principal Accounting Officer of Addex Therapeutics Ltd. (NASDAQ:ADXN), filed a Form 4 on November 13, 2026, disclosing the acquisition of stock options on November 11, 2026.

Anjali Anand | 13 November 2026

Roger Mills Gets 942,854 Stock Options at $0.026 on Nov 11

Addex Therapeutics Ltd. (NASDAQ:ADXN) Chief Medical Officer and Director Roger Mills filed a Form 4 on November 13, 2026, disclosing the acquisition of stock options on November 11, 2026.

Nitish Kishor | 13 November 2026

Addex Director Hill Gets 942,854 Stock Options at $0.026

Director Raymond George Hill of Addex Therapeutics Ltd. filed a Form 4 on November 13, 2026, disclosing the acquisition of 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share.

Aditi Sarkar | 13 November 2026

Lawton Gains 942,854 Addex Stock Options at $0.026

Director Vincent Michael Lawton of Addex Therapeutics Ltd. filed a Form 4 on November 13, 2026, disclosing the acquisition of 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share and an expiration date of October 11, 2036.

Aakashdeep | 13 November 2026
Support

Hi! How can we help you today?

Loading…